What do systematic reviews say?

HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day)

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin plus aspirin vs aspirin

• Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 140 participants
  GRADE not reported

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  OR 0.97 [0.19, 4.81]
  4 studies · 1146 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  OR 1.29 [0.82, 2.03]
  4 studies · 1146 participants
  Low

Anti‐EGFR therapy vs placebo or usual care

Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).

• Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
  OR 3.69 [0.51, 26.51]
  4 studies · 1146 participants
  Low

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

It is very uncertain whether targeted or adjustable individualized fortification changes osteopenia compared with standard non‐individualized fortification (very low certainty).

• Individualized versus standard diet fortification for growth and development in preterm infants receiving human milk 2020 · Cochrane Headline outcomes only
  RR 0.86 [0.4, 1.84]
  1 study · 60 participants
  Very low

Alteplase vs urokinase

Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 0.46 [0.04, 5.24]
  1 study · 99 participants
  Low

Streptokinase vs urokinase

Streptokinase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 1 [0.13, 7.72]
  1 study · 50 participants
  Low

Bispectral index vs clinical signs

• Bispectral index for improving intraoperative awareness and early postoperative recovery in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 1494 participants
  Low

Bispectral index vs ETAG

The review found no eligible studies for this question.

• Bispectral index for improving intraoperative awareness and early postoperative recovery in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 5.26 [2.87, 9.63]
  4 studies · 593 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to lower leucopenia compared with antimetabolites: secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.43 [0.33, 0.56]
  15 studies · 8396 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with antimetabolites: secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 1.96 [1.38, 2.79]
  8 studies · 5028 participants
  Low

Intervention not reported

The intervention showed no clear difference in leucopenia (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.99 [0.7, 1.4]
  5 studies · 1012 participants
  Moderate

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.58 [0.44, 0.75]
  9 studies · 2242 participants
  Low

Intervention not reported

The intervention probably leads to lower all VTE (subgroup analysis open only) (moderate certainty).

• Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery 2019 · Cochrane Headline outcomes only
  OR 0.42 [0.29, 0.6]
  6 studies · 1503 participants
  Moderate

Intervention not reported

The intervention probably leads to lower all DVT (subgroup analysis open only) (moderate certainty).

• Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery 2019 · Cochrane Headline outcomes only
  OR 0.43 [0.3, 0.62]
  6 studies · 1503 participants
  Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 1.43 [0.89, 2.31]
  23 studies · 34154 participants
  Moderate